457 related articles for article (PubMed ID: 25736732)
1. Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment?
Huland H; Graefen M
Eur Urol; 2015 Aug; 68(2):175-8. PubMed ID: 25736732
[TBL] [Abstract][Full Text] [Related]
2. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
3. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Yousefi K; Davicioni E; Ghadessi M; Johnson MH; Sundi D; Tosoian JJ; Han M; Humphreys EB; Partin AW; Walsh PC; Trock BJ; Schaeffer EM
Eur Urol; 2016 Mar; 69(3):496-504. PubMed ID: 25922274
[TBL] [Abstract][Full Text] [Related]
4. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
[TBL] [Abstract][Full Text] [Related]
6. Changing nationwide trends away from overtreatment among patients undergoing radical prostatectomy over the past 25 years.
Meissner VH; Glöckler V; Jahnen M; Schiele S; Gschwend JE; Herkommer K
World J Urol; 2023 Jun; 41(6):1497-1502. PubMed ID: 37195312
[TBL] [Abstract][Full Text] [Related]
7. Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification.
Abdollah F; Boorjian S; Cozzarini C; Suardi N; Sun M; Fiorino C; di Muzio N; Karakiewicz PI; Montorsi F; Karnes RJ; Briganti A
Eur Urol; 2013 Oct; 64(4):557-64. PubMed ID: 23506833
[TBL] [Abstract][Full Text] [Related]
8. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
[TBL] [Abstract][Full Text] [Related]
9. Upgrading and upstaging at radical prostatectomy in the post-prostate-specific antigen screening era: an effect of delayed diagnosis or a shift in patient selection?
Edmund L; Rotker KL; Lakis NS; Brito JM; Lepe M; Lombardo KA; Renzulli JF; Matoso A
Hum Pathol; 2017 Jan; 59():87-93. PubMed ID: 27720731
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer.
Joniau S; Spahn M; Briganti A; Gandaglia G; Tombal B; Tosco L; Marchioro G; Hsu CY; Walz J; Kneitz B; Bader P; Frohneberg D; Tizzani A; Graefen M; van Cangh P; Karnes RJ; Montorsi F; van Poppel H; Gontero P;
Eur Urol; 2015 Feb; 67(2):319-25. PubMed ID: 24684960
[TBL] [Abstract][Full Text] [Related]
11. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
12. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
[TBL] [Abstract][Full Text] [Related]
13. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
Seiler D; Randazzo M; Klotz L; Grobholz R; Baumgartner M; Isbarn H; Recker F; Kwiatkowski M
BJU Int; 2012 Jul; 110(2):195-200. PubMed ID: 22093744
[TBL] [Abstract][Full Text] [Related]
14. Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment.
van den Bergh R; Gandaglia G; Tilki D; Borgmann H; Ost P; Surcel C; Valerio M; Sooriakumaran P; Salomon L; Briganti A; Graefen M; van der Poel H; de la Taille A; Montorsi F; Ploussard G;
Eur Urol Focus; 2019 Mar; 5(2):171-178. PubMed ID: 28801241
[TBL] [Abstract][Full Text] [Related]
15. Low-risk Prostate Cancer: Identification, Management, and Outcomes.
Moschini M; Carroll PR; Eggener SE; Epstein JI; Graefen M; Montironi R; Parker C
Eur Urol; 2017 Aug; 72(2):238-249. PubMed ID: 28318726
[TBL] [Abstract][Full Text] [Related]
16. Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer.
Coley RY; Zeger SL; Mamawala M; Pienta KJ; Carter HB
Eur Urol; 2017 Jul; 72(1):135-141. PubMed ID: 27523594
[TBL] [Abstract][Full Text] [Related]
17. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
18. Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.
Wenzel M; Würnschimmel C; Chierigo F; Tian Z; Shariat SF; Terrone C; Saad F; Tilki D; Graefen M; Mandel P; Kluth LA; Chun FKH; Karakiewicz PI
Prostate; 2021 Aug; 81(11):728-735. PubMed ID: 34010465
[TBL] [Abstract][Full Text] [Related]
19. Migration in last decade to high-risk prostate cancer after radical prostatectomy.
Patard PM; Roumiguié M; Prudhomme T; Doumerc N; Thoulouzan M; Gamé X; de la Taille A; Rischmann P; Soulié M; Salomon L; Beauval JB
Prog Urol; 2019 Jan; 29(1):29-35. PubMed ID: 30337057
[TBL] [Abstract][Full Text] [Related]
20. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
